Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of this study is to determine the influence of social factors on participation and activity among children and adolescents aged 10-18 years with hodgkin-lymphoma. Furthermore personal and treatment-related factors and their impact on participation will be explored.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Functional and Structural Outcomes Following Childhood Bone or Soft Tissue Sarcomas of the Lower Extremity

NCT06737172

Soft Tissue Sarcoma of the Lower Extremity Bone Sarcoma of the Lower Extremity Childhood and Adolescent Cancer

ENROLLING_BY_INVITATION

Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma

NCT00891722

Brain and Central Nervous System Tumors

UNKNOWN

Long Term Implications of Rare Brain Tumours'

NCT04708548

Quality of Life Cognitive Impairment WHO Grade II Oligodendroglial Tumor +3 more

COMPLETED

Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families

NCT05245123

Neuroblastoma Nephroblastoma Hepatoblastoma

COMPLETED

Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas

NCT06323408

Glioma, Malignant Embryonal Tumor Medulloblastoma +1 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hodgkin-lymphoma is a rare malignancy among children and adolescents (about 140 each year in Germany) which is highly curable. Beside this therapeutic success, a lot of therapy-related long-term problems arise (e.g. fertility disorders, thyroid diseases, secondary malignancies). While most of the studies focused on mental and physical impairments, little attention has been drawn to social dimensions of health. Due to the disease and the requirements of the therapy, participation of children with hodgkin-lymphoma can be impaired acutely or chronically. This can be of serious consequences, because participation in daily life is an important component of the development of children and adolescents. To determine the influence of social, personal and treatment-related factors on participation, all patients who were actual treated in the international therapy study EuroNet-PHL-C2 in all of Germany (N ≈ 700) and their parents will be interviewed. Statistical analyses will be done using descriptive and multivariate methods taking account of treatment-related issues (e.g. stage of disease, chemotherapy, radiotherapy, progression/relapse).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Classical Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hodgkin-lymphoma

Children and adolescents aged 10-18 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed primary diagnosis of classical Hodgkin's Lymphoma
* 10-18 years
* written informed consent of the patient and/or the patient's parents or guardian according to national laws